Cargando…

Regional siderosis: a new challenge for iron chelation therapy

The traditional role of iron chelation therapy has been to reduce body iron burden via chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary routes. In their present use for hemosiderosis, chelation regimens might not be suitable for treating disorders o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabantchik, Zvi Ioav, Munnich, Arnold, Youdim, Moussa B., Devos, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875873/ https://www.ncbi.nlm.nih.gov/pubmed/24427136 http://dx.doi.org/10.3389/fphar.2013.00167

Ejemplares similares

In Search for Symbolic Qualities of Iron: The Metal of Life
por: Cabantchik, Zvi Ioav
Publicado: (2016)

Labile iron in cells and body fluids: physiology, pathology, and pharmacology
por: Cabantchik, Zvi Ioav
Publicado: (2014)

Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major
por: Baksi, A. John, et al.
Publicado: (2014)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
por: Grolez, Guillaume, et al.
Publicado: (2015)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and Aging
por: Kupershmidt, Lana, et al.
Publicado: (2023)

Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
por: Moreau, Caroline, et al.
Publicado: (2018)

Physiological and pathological aspects of Aβ in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators
por: Avramovich-Tirosh, Yael, et al.
Publicado: (2008)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
por: Tanner, Mark A, et al.
Publicado: (2008)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

A Novel Antioxidant Multitarget Iron Chelator M30 Protects Hepatocytes against Ethanol-Induced Injury
por: Xiao, Jia, et al.
Publicado: (2015)

Eliezer Rachmilewitz (1935–2017)
por: Cabantchik, Ioav, et al.
Publicado: (2018)

Naringin Chelates Excessive Iron and Prevents the Formation of Amyloid-Beta Plaques in the Hippocampus of Iron-Overloaded Mice
por: Jahanshahi, Mehrdad, et al.
Publicado: (2021)

Iron-Chelated Polydopamine Decorated Doxorubicin-Loaded Nanodevices for Reactive Oxygen Species Enhanced Cancer Combination Therapy
por: Li, Xu-Jing, et al.
Publicado: (2019)

Iron Overload and Apoptosis of HL-1 Cardiomyocytes: Effects of Calcium Channel Blockade
por: Chen, Mei-pian, et al.
Publicado: (2014)

3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy
por: Sarno, Federica, et al.
Publicado: (2018)

Erythrocytapheresis in Children and Young Adults with Hemoglobinopathies and Iron Overload in Need of Iron Chelation Therapy
por: van Hattem, Jessica, et al.
Publicado: (2023)

Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease
por: Knezović, Ana, et al.
Publicado: (2012)

Superficial siderosis
por: Vyas, Sameer, et al.
Publicado: (2011)

Industrial Siderosis
por: Doig, A. T.
Publicado: (1949)

New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases
por: Nuñez, Marco T., et al.
Publicado: (2018)

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease
por: Nuñez, Marco T., et al.
Publicado: (2019)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Vaccine efficacy and iron deficiency: an intertwined pair?
por: Drakesmith, Hal, et al.
Publicado: (2021)

Vestibular function in superficial siderosis
por: Miwa, Toru, et al.
Publicado: (2013)

Bilateral Vestibulopathy in Superficial Siderosis
por: Lee, Sang-Yeon, et al.
Publicado: (2018)

Advances in iron chelation therapy: transitioning to a new oral formulation
por: Shah, Nirmish R.
Publicado: (2017)

Adherence to Iron Chelation Therapy and Its Determinants
por: Sidhu, Sukhmani, et al.
Publicado: (2021)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Superficial Siderosis and Anticoagulation Therapy: Different Presentations, Different Outcomes
por: Barreto, Rui Duarte, et al.
Publicado: (2012)

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
por: Unzeta, Mercedes, et al.
Publicado: (2016)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

A Combined Drug Treatment That Reduces Mitochondrial Iron and Reactive Oxygen Levels Recovers Insulin Secretion in NAF-1-Deficient Pancreatic Cells
por: Karmi, Ola, et al.
Publicado: (2021)

Therapeutic Potential of Iron Chelating Therapy: Modification of Disease by Iron Depletion
por: Hershko, Chaim, et al.
Publicado: (1994)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Superficial siderosis in cerebral amyloid angiopathy
por: Wani, Nisar Ahmad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_n9tsl3l7reccmmjdng6rel02or